Oncology Therapeutics
Prelude Therapeutics news and milestones
Prelude Therapeutics: 23 headlines on record, 5 headlines in the last 90 days. Its story counts 9 milestones.
Data updated Nov 17, 2026 · Back to the company report
23Headlines
5In 90 days
9Milestones
Headlines
Oct 72026
Blog
Ryan Holmes, Associate Director, Chemistry on behalf of the DAC team The post Precision Degrader Antibody Conjugates (DACs): An Emerging Modality in Targeted Therapeutics appeare…
Sep 232026
News · Prelude Therapeutics stock falls 9.9 percent despite FDA progress
Prelude Therapeutics stock traded at USD 4.37 on Nasdaq on September 23, 2026, while Q2 revenue reached USD 5.7 million. Q2 net loss was USD 13.9 million.
Sep 202026
News · Prelude Therapeutics stock gains as FDA clears new breast cancer drug trial
Prelude Therapeutics stock has risen strongly in recent weeks after FDA clearance of the IND for breast cancer candidate PRT13722, with shares closing at USD 4.87 on September 18…
Sep 102026
News · YahooFinance
Phase 1 study of PRT13722 in patients with HR+ breast cancer anticipated to begin enrolling patients in the fourth quarter of 2026.WILMINGTON, Del., Sept. 10, 2026 (GLOBE NEWSWIR…
Aug 222026
News · Pulse 2.0
Prelude Therapeutics reduced its second-quarter 2026 net loss by approximately 55% year-over-year as research and development spending declined sharply following the pausing of p…
Jul 222026
Blog
Ryan Holmes, Andrew Moore, Max Foroutan, Jake Karwoski, Alex Grego, Carly Bachner1 Neha Bhagawat, Corey Basch, Soham Maity, Chun Chen, Sarah B. Pawley, Vijay Devannah, Sina Rezaz…
Apr 202026
Blog
Monisha Sivakumar, Sarah Pawley, Corey Basch, Jimin Park, Justin Kurian, Anthony Reichelderfer, Yue Zou, Kirsten Gallagher, Miles Cowart, Joy Cote, Alexander Grego, Jessica Burte…
Apr 202026
News · seekingalpha.com
Apr 152026
Blog
Koichi Ito, PhD Senior Director, Biology and Pharmacology, Prelude Therapeutics Incorporated The post Beyond Conventional Payloads: Unlocking New Therapeutic Landscapes With Prec…
Mar 152026
Blog
Andrew W. Buesking, Sr. Director, Chemistry on behalf of the pDAC team The post Discovery of precision degrader antibody conjugates (pDACs) employing novel SMARCA2/4 degrader pay…
Dec 6, 20252025
Blog
Norman Fultang1, Ashley Schwab1, Sharayu Chandratre1, Jake Karwoski1, Grace Davis1, Ian Johnson1, Neha Bhagwat1, Yue Zou1, Arpita Mondal1, Max Foroutan1, Min Wang1, Andrew Bueski…
Dec 6, 20252025
Blog
Neha Bhagwat1, Duanya Liu2, Xiaowei Wu1, Alexander Grego1, Amy Crossan1, Andrew Moore1, Arpita Mondal1, Carly Bachner1, Dani Roth1, Diego Elrio, John Rose1, Joseph Rager1, Joy Co…
Nov 8, 20252025
News · YahooFinance
Prelude Therapeutics, a clinical-stage biotech, has attracted fresh attention after securing an option agreement with Incyte for its JAK2V617F inhibitor program. The deal brings…
Nov 4, 20252025
News · seekingalpha.com
Nov 4, 20252025
Blog
Sri Sahasranaman is Senior Vice President of Clinical Pharmacology at Prelude Therapeutics and is responsible for leading and overseeing clinical pharmacology and pharmacometrics…
Nov 4, 20252025
News · SeekingAlpha
Prelude Therapeutics Incorporated continues to explore the SMARCA2 anticancer approach. Click here to read why PRLD stock is a Hold.
Aug 11, 20252025
News · YahooFinance
NasdaqGS:PRLD 1 Year Share Price vs Fair Value Explore Prelude Therapeutics
Jun 18, 20252025
Blog
Wojciech Jurczak, Clementine Sarkozy, Katharine L. Lewis, Geoffrey Shouse, Eliza A. Hawkes, Won Seog Kim, Monica Tani, François Lemonnier, Sarit E. Assouline, Franck Morschhauser…
Jun 18, 20252025
Blog
Norman Fultang, Ashley Schwab, Sharayu Chandratre, Ian Johnson, Jake Karwoski, Neha Bhagwat, Arpita Mondal, Min Wang, Yue Zou, Andrew Buesking, Max Foroutan, Chun Chen, Corey Bas…
May 31, 20252025
Blog
Timothy A. Yap, MD, PhD; Martin E. Gutierrez, MD; Wade T. Iams, MD; Victor Moreno, MD, PhD; Tatiana Hernández Guerrero, MD, PhD; Guzmán Alonso, MD; Carlos A. Gomez-Roca, MD; Soph…
Apr 24, 20252025
News · Nasdaq
Prelude Therapeutics presents preclinical data on SMARCA2 and KAT6A degraders, highlighting their potential cancer treatment advantages.
Dec 22, 20242024
News · YahooFinance
Whilst it may not be a huge deal, we thought it was good to see that the Prelude Therapeutics Incorporated...
Oct 25, 20242024
News · Nasdaq
Barclays analyst Peter Lawson lowered the firm's price target on Prelude Therapeutics (PRLD) to $1 from $3 and keeps an Underweight rating on the shares. The updated SMARCA2 degr…
Sources: the outlets named on each headline, each story once
Milestones
Aug 21, 2020
May 31, 2019
Jun 27, 2016
2016
Founded
Each milestone is dated by its source: registers, filings, the press
How to cite
Prelude Therapeutics, News. Alion, Nov 17, 2026. https://alion.io/company/world-3783071/news
